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AbstrACt
Objective To explore experts’ views on factors influencing 
national and global active case- finding (ACF) policy 
development and implementation, and the use of evidence 
in these processes.
Design This is an exploratory study based on 
semistructured expert interviews. Framework analysis was 
applied.
Participants The study involved a purposive sample 
of 39 experts from international, non- governmental and 
non- profit organisations, funders, government institutions, 
international societies, think tanks, universities and 
research institutions worldwide.
results This study highlighted the perceived need among 
experts for different types of evidence for ACF policy 
development and implementation, and for stakeholder 
engagement including researchers and policymakers to 
foster evidence use. Interviewees stressed the influence 
of government, donor and non- governmental stakeholders 
in ACF policy development. Such key stakeholders also 
influence ACF policy implementation, in addition to 
available systems and processes in a given health system, 
and implementers’ motivation and incentives. According 
to the interviewees, the World Health Organization (WHO) 
guidelines for systematic screening face the innate 
challenge of providing guidance to countries across the 
broad area of ACF in terms of target groups, settings and 
screening algorithms. The guidelines could be improved by 
focusing on what should be done rather than what can be 
done in ACF, and by providing howto examples. Leadership, 
integration into health systems and long- term financing 
are key for ACF to be sustainable.
Conclusions We provide new insights into ACF policy 
processes globally, particularly regarding facilitators for 
and barriers to ACF policy development, evidence need 
and use, and donor organisations’ influence. According 
to expert participants, national and global ACF policy 
development and implementation can be improved by 
broadening stakeholder engagement. Meanwhile, using 
diverse evidence to inform ACF policy development and 
implementation could mitigate the ‘power plays plus push’ 
that might otherwise disrupt and mislead these policy 
processes.
bACkgrOunD
Tuberculosis (TB) is a major global health 
emergency, especially in low- and middle- 
income countries. TB is curable and prevent-
able. Still, it remains the leading cause of 
death from a single infectious agent and one 
of the top 10 causes of death worldwide.1 In 
2019, the estimated incident TB cases and 
those notified globally resulted in a differ-
ence of 3 million cases, reflecting a combina-
tion of under- reporting of detected TB cases 
and underdiagnosis, specifically in coun-
tries with major financial and geographic 
barriers to accessing care.1 Many people with 
TB are diagnosed only after long delays,2–4 
causing increased morbidity, much suffering 
and economic hardship, and sustaining 
transmission.1
The World Health Organization (WHO) 
End TB Strategy5 was endorsed by member 
states at the World Health Assembly in 2014, 
strengths and limitations of this study
 ► Expert interviews were able to elicit a unique insight 
into active case- finding (ACF) policy development 
and implementation.
 ► Expert interviews filled knowledge gaps regarding 
factors influencing ACF policy development, donors’ 
influence and evidence use in ACF policy processes.
 ► The number and diverse range of experts in-
volved increase the study’s trustworthiness and 
confirmability.
 ► Women and interviewees from low- and middle- 
income countries were under- represented in the 
study, potentially limiting the transferability of the 
results.
 ► We did not systematically conduct analyses by 
stakeholder group but described the patterns we 
observed and highlighted the affiliations of inter-
viewees quoted.
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while the United Nations (UN) Sustainable Develop-
ment Goals6 were adopted in 2015. Both are aimed at 
ending the global TB epidemic. Subsequently, there has 
been increasing international attention on TB. In 2017, 
the Global Ministerial Conference on Ending TB in the 
Sustainable Development Era took place in Russia, with 
the aim of accelerating implementation of the End TB 
Strategy.7 In 2018, the UN held the first- ever General 
Assembly high- level meeting on TB in New York, which 
endorsed a political declaration to speed up progress 
towards ending TB. This declaration was adopted by the 
General Assembly on 10 October 2018.8 Both the Global 
Ministerial Conference and the General Assembly re- em-
phasised the importance of active case- finding (ACF).
Ending TB will require intensified activity to increase TB 
case detection.5 One strategy for increased TB case detec-
tion is systematic screening, which is defined by the WHO 
as the ‘systematic identification of people with suspected 
active TB, in a predetermined target group, using tests, 
examinations or other procedures that can be applied 
rapidly’.9 ACF is synonymous with systematic screening 
for active TB, although it usually implies screening 
outside of health facilities. ACF is mostly provider initi-
ated. It may target people who do not seek appropriate 
healthcare because they: do not have or recognise symp-
toms, do not perceive that they have a health problem 
requiring medical attention, or face barriers in accessing 
appropriate care.9
ACF has been implemented for decades primarily 
in high- income countries, starting with mass screening 
campaigns in the general population in the 1950s and 
1960s, then moving towards specific risk populations in 
recent decades, such as migrants from high- incidence 
countries and prison populations.10 11 In low- and middle- 
income countries, the interest in ACF has increased in 
recent years, mainly as a response to a sustained case 
detection gap documented in TB prevalence surveys, 
annual Global TB Reports produced by WHO1 and the 
development of new WHO guidelines on systematic 
screening.9
Questions remain about both if ACF in general is worth-
while, as well as how to best develop and implement ACF 
in a given context as a synergistic, rather than parallel 
structure to the given health system. The evidence base 
is weak concerning the benefits and cost- effectiveness 
of ACF on both individual and community levels and 
how these vary between target risk groups.12 However, 
potential benefits of ACF for patients include reduced 
morbidity, mortality and socioeconomic consequences 
due to earlier diagnosis, while society can benefit from 
TB infection prevention, reduced transmission and a 
reduced burden of TB.9 There is some evidence that TB 
screening in high- risk groups can significantly increase 
TB case notifications.13–15 Yet, from the health system 
perspective screening can be costly and lead to diversion 
of scarce resources. It can also cause harm to patients, 
for example, by increasing the risk of false- positive diag-
noses, creating an additional financial burden associated 
with attending screening and follow- up, or increased 
stigma and discrimination, if not properly targeted and 
implemented.16
The potential benefits and challenges of ACF need 
to be carefully balanced when designing and imple-
menting ACF. Given the relatively weak evidence base for 
ACF, related policy development and implementation 
processes rely on stakeholders’ tacit knowledge, values 
and preferences. Yet, little is known about the latter, which 
potentially impact the development and implementation 
of national and global ACF policies. The aim of this study 
was to explore the views of experts on the factors that 
influence ACF policy development and implementation, 
and their views of the use of evidence in these processes.
MethODs
This was an exploratory study based on semistructured 
expert interviews.17 The research team used the Consoli-
dated Criteria for Reporting Qualitative Research check-
list18 to report the study (online supplementary file 1).
OB is a doctoral student in public health sciences 
focusing on ACF. She has experience in qualitative 
research. The multidisciplinary research team consisting 
of a medical doctor, an epidemiologist, a microbiologist 
and a social scientist were involved in this study to ensure 
different viewpoints were included on ACF policy devel-
opment and implementation.
recruitment and sample selection
The interviewees were purposively sampled to include 
stakeholders involved in ACF policy development and 
implementation based at international (n=16), non- 
governmental (n=2) and non- profit organisations (n=2), 
funders (n=4), government institutions (n=2), inter-
national societies (such as the International Society of 
Travel Medicine, but in the TB field) (n=2), think tanks 
(n=1), universities (n=6) and research institutions (n=3), 
as well as one independent consultant. The research team 
compiled the initial list of interviewees based on knowl-
edge of networks of experts and on the published scien-
tific literature. The list was discussed with, expanded and 
verified by two independent experts in the field.
The primary investigator (OB) contacted 50 individuals 
via email. Of these, two suggested that their colleagues be 
interviewed instead, eight did not reply and one declined 
participation due to lack of time and interest. Seven of 
the 11 people (64%) who declined participation were 
female. Table 1 provides an overview of the 39 partici-
pants who agreed to participate, their sex, professional 
affiliation and country where they are currently based, 
classified according to the World Bank.19 In the Results 
section, we have used quotes from interviewees across all 
country income levels to increase the dependability of the 
results.20 Moreover, where possible in the results, we have 
tried to reflect all participants’ voices.
Data collection
OB collected the data between February and May 2018 
through semistructured interviews via the phone or in 
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Table 1 Participants and their background information (in chronological order)
ID Sex Affiliation Country classification according to the World Bank19
1 Male University High- income country
2 Male International organisation Low- income country
3 Male Government institution Low- income country
4 Male International organisation Low- income country
5 Male Government institution Low- income country
6 Male International organisation Low- income country
7 Male Non- governmental organisation Low- income country
8 Male Non- governmental organisation Low- income country
9 Female Research institution High- income country
10 Male International organisation High- income country
11 Male International organisation High- income country
12 Male Research institution High- income country
13 Female Non- profit organisation Upper middle- income country
14 Female International society Lower middle- income country
15 Male Funder High- income country
16 Male International organisation High- income country
17 Female International organisation High- income country
18 Male Research institution High- income country
19 Male International organisation High- income country
20 Male University High- income country
21 Male University High- income country
22 Male International society High- income country
23 Female Think tank High- income country
24 Female International organisation High- income country
25 Male International organisation High- income country
26 Male International organisation High- income country
27 Male Independent consultant Lower middle- income country
28 Male International organisation High- income country
29 Male International organisation Lower middle- income country
30 Male Funder High- income country
31 Male Funder Lower middle- income country
32 Male University High- income country
33 Male Funder High- income country
34 Male International organisation Lower middle- income country
35 Male International organisation High- income country
36 Female University Low- income country
37 Male University High- income country
38 Male Non- profit organisation High- income country
39 Male International organisation Upper middle- income country
person. She developed the interview guides (online 
supplementary file 2) which MC, KL and KV provided 
feedback on. The first interview was conducted as a pilot 
interview after which the guide was revised, making it 
shorter to focus on the principal topics of interest.
After providing information about the study and 
obtaining informed written consent, OB asked the inter-
viewees about their experience in developing and/or 
implementing ACF policies, factors that influenced these 
policy processes and the use of evidence. The interviews 
were audio recorded. No repeat interviews were carried 
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Table 2 Example of the coding process
Interviewee Quote Code Category Theme
I-27, independent 
consultant in a lower 
middle- income country
‘So, I think it’s the political 
push that then forces the 
technocrats to develop 
policies.’
Government 
influencing
Government leadership 
and commitment
Factors influencing ACF 
policy development
ACF, active case- finding.
out and no formal field notes were taken. OB conducted 
interviews aiming to ensure that the sample would hold 
adequate information power to develop new knowledge.21 
The large number of participants was deemed necessary 
given the broad aim of the study and that all interviewees 
had extremely relevant experience related to different 
aspects of ACF policy development and implementa-
tion. This allowed capturing opinions from the diverse 
range of experts involved in ACF policy development and 
implementation, but also led to the decision to present 
parts of the results (on the perceived benefits and risks of 
ACF) in a separate article to do justice to the breadth and 
depth of the findings.
Eleven interviews were carried out in person; out of 
these, eight interviews were conducted during a field visit 
to Nepal, two during WHO meetings and one during a visit 
to an international organisation. During the interviews, 
only OB and the respective interviewee were present. The 
typical duration of an interview was 30–60 minutes. OB 
transcribed 10 of the audio- recorded interviews verbatim, 
while the remaining ones were transcribed by a profes-
sional company. The anonymity and confidentiality of the 
participants were ensured by unique assigned number 
codes and removing all identifiers except the respondent 
affiliation in the presentation of the results. OB offered 
all participants the opportunity to view their transcripts 
for comments or correction, however, only three partic-
ipants requested to see the transcripts. No comments or 
corrections were made by those who chose to view the 
transcripts.
Data analysis
OB analysed the qualitative data from the expert inter-
views with NVivo V.11 using framework analysis.17 The 
data were analysed abductively; defining themes a priori, 
while allowing for the identification of additional themes 
based on the data. Using the framework analysis approach 
as described by Gale et al,22 OB coded all interviews and 
developed an analytical framework. SA and KV provided 
comments on the coding, based on which OB revised 
the codes. The data were then charted into a framework 
matrix, on which SA and KV provided feedback. OB inter-
preted the data by writing memos for each study theme, 
and discussed these with SA, KL and KV. Table 2 provides 
an example of the coding process.
Patient and public involvement
The preliminary findings were shared at three different 
scientific conferences in 2018. The interaction with 
participants of these events provided unique opportuni-
ties for validating the findings. For the presentation of 
preliminary findings at the World Union Conference 
on Lung Health, personalised invitations were sent to 
all 39 interviewees. A few interviewees attended and two 
provided feedback. As such, the presentation of prelimi-
nary findings gave an opportunity for member checking. 
No direct changes were made based on the validation 
and member checking, but these processes helped to 
more critically reflect on the findings. Once published, 
the results of this study will be reported back to all inter-
viewees. In addition, targeted issue briefs will be devel-
oped for researchers and decision- makers in the field. We 
will also share the results with the public via a video and 
short messages on social media.
results
We generated the following themes from the data: (1) 
evidence generation and use, (2) factors influencing ACF 
policy development, (3) factors influencing ACF policy 
implementation, (4) WHO guidelines on systematic 
screening, and (5) sustainability of ACF. Table 3 provides 
an overview of the five main themes and the 16 related 
codes. The benefits and risks of ACF were additional 
major themes which will be analysed and discussed in a 
separate publication. Overall, the interviewees had a wide 
variety of views on ACF; from ACF being a ‘waste basket’ for 
resources to it being ‘common sense’.
theme 1: evidence generation and use
Most interviewees described the evidence on ACF as being 
relatively limited and emphasised the need to generate 
different types of evidence to inform ACF policy devel-
opment and implementation. They stressed the impor-
tance of disseminating and exchanging evidence, of the 
demand for evidence by decision- makers and stakeholder 
engagement to enable evidence use. Apart from high-
lighting specific types of evidence, interviewees across 
the different settings had similar views with regard to this 
theme.
Interviewees highlighted that a variety of evidence is 
needed and demanded by decision- makers working on 
ACF; from effectiveness and health economic evaluations 
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Table 3 Summary of major themes and categories related 
to ACF policy development and implementation
1 Evidence generation 
and use
1 Dissemination and 
exchange of evidence
2 Demand for evidence by 
decision- makers
3 Stakeholder engagement 
to facilitate evidence use
2 Factors influencing 
ACF policy 
development
1 Government leadership 
and commitment
2 Donor funding
3 Non- governmental 
organisations’ experience
3 Factors influencing 
ACF policy 
implementation
1 Human and financial 
resources
2 Systems, processes and 
resources to build on
3 Donor funding and related 
target setting
4 Government power
5 Health workers’ 
motivation and incentives
4 WHO guidelines on 
systematic screening
1 Positive and negative 
perceptions
2 Contextualisation of 
global guidelines locally
3 Suggested improvements
5 Sustainability of ACF 1 Opportunities for 
sustainability
2 Challenges for 
sustainability
ACF, active case- finding.
to implementation and operational research. One 
interviewee from a university in a high- income country 
stressed that to demonstrate effectiveness, there is a need 
‘to do ACF in the context of randomized controlled trials’ (I-32). 
Another interviewee from a non- governmental organi-
sation (NGO) in a low- income country highlighted the 
importance of distinguishing clearly where the deci-
sions are being made; be it at the community, district or 
national level:
I think this is very important, ie what types of evi-
dence you would need to make decisions at various 
levels (…). What evidence is enough evidence at what 
level to take the decision. (I-7)
Local evidence was said by many to play a significant 
role in, for instance, available health and diagnostic facil-
ities, and health workers’ capacity and experience in 
communicating with communities. In particular, evidence 
from national TB prevalence surveys was described as 
significant for TB policy development more broadly. Two 
interviewees from funding organisations in high- income 
countries concluded that countries should be encour-
aged ‘to adopt [ACF] policies based on the local evidence and 
then move forward, rather than waiting for systematic reviews’ 
(I-30) and ‘you should implement enough to figure out what’s 
practicable and what works, and then that should become policy’ 
(I-15). According to the interviewees, evidence use in 
ACF policy development and implementation necessi-
tates evidence dissemination and exchange, especially 
to share unpublished findings. One interviewee from an 
international organisation highlighted:
Unfortunately, we are [from a low- income country] 
and we are not very good at publishing. We’ve got a 
wealth of experience that is unpublished (…) but it 
has been presented at several conferences. (I-35)
Depending on the country context, gaps may exist 
between evidence and policy and/or between policy and 
practice. As one interviewee from an international organ-
isation in a high- income country pointed out:
Countries are different. As I said, in [that country] 
(…) from evidence to policy was difficult. But once it 
[ACF] was inside the policy or even without the poli-
cy, they used to easily convert it to practice. But here 
[in our country] (…) evidence to policy is easier, but 
policy to practice is more difficult. (I-28)
Interviewees emphasised that researchers should 
engage with key stakeholders from the beginning of the 
research process to foster research use in ACF policy devel-
opment and implementation; stakeholders may include 
the WHO, the Ministry of Health and the National TB 
Programme.
‘Make sure that you have the right partners from the 
beginning; partners who are going to take your re-
sults and actually do something with them. Because 
otherwise you are kind of doing it [research on ACF] 
in a vacuum,’ said one interviewee from a university 
in a high- income country. (I-37)
Moreover, to spark dialogue through stakeholder 
engagement, an interviewee from an NGO in a low- 
income country stressed that one must ‘create platforms, 
or you need to use the platforms which are already there’ (I-7). 
Regular review meetings at subnational and national 
levels to discuss challenges and successes related to ACF 
offer one such platform. Overall, evidence use was said to 
be influenced by who is being engaged and by personal 
contacts which may be ‘more important than they should be’, 
as another interviewee from a university in a low- income 
country described (I-36).
theme 2: factors influencing ACF policy development
According to the interviewees, many different stake-
holders influence ACF policy development, specifically 
governments, donors and NGOs. Interviewees under-
lined stakeholder involvement as being necessary for 
policy development and the contextualisation of global 
policy into local realities. Interviewees did not have any 
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contradicting views with regard to this theme, but rather 
highlighted the specific roles of certain stakeholders they 
thought were most influential in ACF policy development. 
The leadership, buy- in and commitment of governments 
and National TB Programmes were described as being 
vital for ACF policy development and implementation. 
India was mentioned as a prime example where political 
push ‘forced the technocrats to develop policies and implement 
them’ (I-27, an independent consultant in a lower middle- 
income country). Governments make decisions for polit-
ical reasons or donor incentives, even if these contradict 
the evidence. One representative from an international 
organisation in a high- income country highlighted an 
example of action perceived to be contradicting their 
view of the evidence:
Women and children of reproductive age (…) should 
only be included as part of the passive system not as 
a priority for ACF ever. But when you talk to NTP 
[National TB Programme] managers, there is strong 
political pressure and a perception that donors want 
them to focus on women and children. (I-24)
Donor organisations such as the Global Fund to Fight 
AIDS, Tuberculosis and Malaria and the case- finding initi-
ative TB REACH (the latter is coordinated by the Stop TB 
Partnership and funded largely by Global Affairs Canada) 
were described as being influential in ACF policy develop-
ment, for example, TB REACH was said to have ‘brought 
this concept of ACF to the country’ (I-2, interviewee from 
an international organisation in a low- income country), 
while the Global Fund ‘hold[s] every power to change things 
and not to change things’ regarding ACF policy develop-
ment (I-7, representative from an NGO in a low- income 
country). Likewise, interviewees pointed out that donors’ 
influence was linked to WHO’s influence, as donors 
request countries to adopt WHO guidelines to be eligible 
for funding:
‘Why national policymakers are looking mainly at 
things like WHO documents: because a lot of them 
get Global Fund money and Global Fund money is 
often aligned with countries implementing WHO 
policies,’ described an interviewee who is based at a 
research institution in a high- income country. (I-9)
This observation was shared by another interviewee, 
from an NGO in a low- income country (I-8). Linking 
back to the preceding theme on evidence generation and 
use, TB REACH projects have the potential to generate 
useful evidence for future policy and practice, as an inde-
pendent consultant in a lower middle- income country 
pointed out (I-27). Interviewees said that NGOs are often 
the ‘implementers’ of ACF whose years of experience 
are of great value for ACF policy development and they 
should therefore be involved in the same, for instance, 
in policy dialogues with the government and other key 
stakeholders. One representative of an NGO in a low- 
income country stated:
We [NGOs] are the one who really deal with the peo-
ple (…). We have the evidence. We have the good 
photographs. We have the data. (…) We are the ones 
who can influence [ACF policy development]. (I-8)
theme 3: factors influencing ACF policy implementation
Interviewees elaborated on available resources, systems 
and processes within a given health system, donor and 
government stakeholders, as well as the motivation and 
incentives for health workers as major factors influencing 
ACF policy implementation. Interviewees emphasised the 
role of particular stakeholders, as well as barriers and facil-
itators they thought were most influential in ACF policy 
implementation, while no clearly contradictory views on 
this theme emerged. The implementation and scale- up 
of ACF policies depend on the availability of financial 
resources, as many interviewees stressed.
‘We realized that in a country like [our country], we 
have great policies. The problem is the implementa-
tion. (…) And this is where the support of the de-
velopment partners, funded through PEPFAR [The 
President's Emergency Plan For AIDS Relief], have 
been key to implement these policies, particularly 
ACF policies,’ one interviewee described. (I-39, inter-
viewee from an international organisation in an up-
per middle- income country)
ACF implementation may ‘just stop because [there is] no 
funding’ (I-29, interviewee from an international organ-
isation in a lower middle- income country). An inter-
viewee from a funding organisation in a high- income 
country provided a different perspective regarding the 
funding for ACF by highlighting that ‘ACF through govern-
ment funding can be more difficult than doing it through donor 
funding’ (I-15). This perspective may inhibit long- term 
thinking about ACF, as it seems to focus on immediate 
action to implement rather than sustainability, which 
is more likely to come with government investment. In 
addition to limited financial resources, human resource 
constraints for ACF were highlighted as a major challenge 
by experts from low-, middle- and high- income countries. 
These constraints could hinder National TB Programmes 
in thinking more strategically and ambitiously about how 
to address TB comprehensively.
The use of existing systems and processes in a given 
health system was said to be central because ‘if you start 
from scratch, it [ACF] is much more difficult than if there are 
already things to which you can link,’ as an interviewee from 
an international organisation in a high- income country 
pointed out (I-17). Interviewees mentioned that ACF 
policy implementation can build on experience from 
existing screening programmes (eg, cervical cancer 
screening), activities for vulnerable populations (eg, 
needle exchange programmes), healthcare infrastruc-
ture (eg, chest X- ray buses) and already known locations 
for screening in high- incidence areas and trained human 
resources (eg, those involved in prevalence surveys). Yet, 
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pursuing synergies may be challenging due to the frag-
mentation of activities. In addition, the structure and 
financing of TB within a health system matters in terms of 
availability of resources:
‘TB has tended to fall into the preventative [arm of 
the health system] and that has limited the availabili-
ty for resources,’ described an interviewee from a uni-
versity in a high- income country. (I-32)
Processes including supportive supervision, monitoring 
and the use of standard operating procedures are crit-
ical for ACF policy implementation and are necessary to 
avoid corruption, interviewees discussed. In one country, 
the ‘whole case- finding system collapsed along with the super-
vision’ (I-16, interviewee from an international organi-
sation in a high- income country). Moreover, processes 
that strengthen communication with, engagement of and 
awareness raising among communities were described 
as instrumental for ACF policy implementation, for 
example, to help reduce stigma. One interviewee from a 
university in a high- income country mentioned how the 
community ‘has started to advocate loudly for ACF services’ 
(I-20).
Many interviewees underlined that donors influence 
the implementation of ACF policies in countries with no 
or insufficient domestic resources. ‘The piper will determine 
what music you play’ (I-35, interviewee from an interna-
tional organisation in a high- income country), which, 
again, highlights the power which donor organisations 
are perceived to have in influencing ACF policy imple-
mentation, and the possible resulting lack of a sense of 
policy ownership in some countries. Donors influence 
ACF policy implementation by setting targets for their 
funding recipients and pushing them towards reaching 
them. One interviewee from an international organisa-
tion in a high- income country described:
These targets that countries have set, that donors 
have set; people are very anxious (…) and that often 
means the easiest short cut is to do ACF, even if it is 
a little bit unethical or little bit using low specificity 
tools, so you have a little bit of over diagnosis. Donors 
are very comfortable with that. (I-24)
The consequences of implementing ACF under donor 
pressure are unclear and should be balanced against the 
unethical nature of inaction on the TB epidemic, but 
scale- up of inaccurate diagnostic strategies might lead to 
heightening the potential risks of ACF such as increasing 
false- positive diagnoses, as the interviewee mentioned.
ACF policy development and implementation depend 
on ‘power plays plus push’, for instance, in a country with 
no written ACF policy, ACF was still being implemented 
because the National TB Programme manager was 
respected and able to push for it (I-29, interviewee from 
an international organisation in a lower middle- income 
country). The aforementioned pressure by politicians, 
donors and WHO may be seen as additional examples of 
‘power plays plus push’. Many interviewees highlighted the 
important role of power dynamics in ACF policy imple-
mentation. It seems crucial to be aware of such dynamics, 
while the use of evidence may help mitigate them. ACF 
policy implementation is in itself a balancing act, which 
power imbalances might negatively impact.
The motivation of health workers and volunteers is an 
important enabler for ACF policy implementation. These 
‘implementers’ can be strongly motivated by their desire 
to help people, by understanding the benefit of ACF for 
communities, by receiving feedback on the outcomes of 
their work (eg, using performance indicators) and/or by 
feeling ownership of the ACF process, according to the 
interviewees. Financial and non- financial incentives (eg, 
salaries, transportation allowances, provision of motor-
bikes or mobile airtime) have a significant role in moti-
vating health workers and volunteers to implement ACF 
as an outreach activity, interviewees discussed. Neverthe-
less, incentives can raise expectations and distort ACF 
policy implementation in the long term, for example, 
if government health workers are paid extra as part of 
an ACF project, they will also expect an extra pay for 
such activities in the future and for other work; another 
balancing act. While incentives should be in line with 
what a country could adopt later, they are often difficult 
or impossible for governments to sustain, an interviewee 
said.
theme 4: WhO guidelines on systematic screening
This theme focuses on stakeholders’ perceptions of the 
WHO guidelines on systematic screening, the need for 
their contextualisation and suggestions for improving 
them. This theme elicited different views among stake-
holders, which are described in the following.
The WHO guidelines on systematic screening are 
perceived positively by many, for instance, as a refer-
ence document when planning ACF activities as well as 
to put ACF on the agenda. Positive perceptions of the 
guidelines were described by interviewees from different 
countries, while negative perceptions were only voiced 
by interviewees in high- income countries. Such negative 
perceptions included the guidelines being vague, lacking 
information about the how- to of ACF and being unduly 
negative in terms of mentioning the risk of increasing 
false- positive diagnoses through ACF. Low- income coun-
tries may be more receptive to and reliant on WHO 
guidelines, while in a middle- income country ‘you’ve got 
really serious domestic universities providing the formal policy 
evidence. And the country kind of says “Thanks but no thanks” 
to outside opinions. They are really driving their own decisions. 
WHO is really not consulted very much, if at all,’ a represen-
tative of a funding organisation in a high- income country 
described (I-15). An interviewee from an international 
organisation in a high- income country said:
When you have something that is so broad—and 
you’re talking about ACF which can be so many dif-
ferent things—it’s just very hard to have something 
that works the same way in different countries (…). I 
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think that’s the main shortcoming around the guid-
ance. (I-28)
Interviewees emphasised the necessity of contextual-
ising the WHO guidelines on systematic screening, for 
example, depending on a country’s income level, epide-
miology and availability of diagnostic tools. One inter-
viewee from a funding organisation in a high- income 
country pointed out that ‘you just can’t be as prescriptive 
and exact as you are in the more clinical guidelines’ (I-15), 
which seems like an important observation and reminder 
about the limitations that ACF policies will always have. 
According to the interviewees, contextualisation of guide-
lines can happen in a stepwise approach, for instance, a 
country pilots the use of a guideline before adopting and 
adapting it.
Review meetings with WHO and other partners can 
provide a platform for discussions around guideline 
adaptation, interviewees said. Yet, countries have faced 
challenges in contextualisation, for example, WHO 
recommends using chest X- ray which was too expensive 
in a country and could thus not be used. In another 
instance, WHO describes how contacts of an index patient 
with TB should provide their address, while individuals 
were hesitant to do so due to the stigma surrounding TB 
in the country. More support for the contextualisation of 
guidelines may be needed.
The interviewees suggested that the WHO guidelines 
for systematic screening9 must be updated based on new 
evidence, for instance, evidence from prevalence surveys, 
gender analyses, studies about specific risk groups (eg, 
drug users and indigenous populations) and what works 
and how, with regard to ACF. In this process, WHO should 
be aware of and avoid conflicts of interest, for example, 
by ensuring potential conflicts of interests are adequately 
declared and managed. This comment is in line with 
what an interviewee previously highlighted about the 
role of personal contacts to bridge the research–policy 
gap. These types of biases may undermine the integrity 
of the process and the resulting quality of guidelines and 
policies.
Some interviewees lamented that WHO can be para-
lysed by the need to use the strongest evidence available 
and suggested that the organisation should consider 
more programmatic, less scientifically rigorous data. One 
interviewee from a university in a high- income country 
described:
Usually we’re relying very heavily on WHO for glob-
al policy using the GRADE approach [Grading of 
Recommendations Assessment, Development and 
Evaluation was developed for creating summaries 
of research evidence to help guide health decision- 
making. It is currently the most widely used tool 
for evaluating the quality of science, with more 
than 110 organisations endorsing the method.23] 
with the PICO [P—Patient, Problem or Population; 
I—Intervention; C—Comparison, Control or 
Comparator; O—Outcome(s). The PICO process 
or framework is a mnemonic used in evidence- based 
practice to frame and answer a clinical or healthcare- 
related question. The PICO framework is also used to 
develop literature search strategies, eg, in systematic 
reviews.24] and all that stuff. I think that’s laudable, 
but sometimes I find that weird, subjected to the tyr-
anny of the great process, and you don’t make prog-
ress in smaller areas with a paucity of evidence. (I-21)
In addition, interviewees pointed out that WHO recom-
mendations should be based on what should be done, not 
on what can be done. For example, countries (not WHO) 
have to be the ones to decide about their ability to pay for 
Xpert MTB/RIF as a diagnostic tool. This point of view 
illustrates a stark contrast to the contextualisation chal-
lenges mentioned above, for instance, where the use of 
X- ray was recommended, but, frustratingly, was unable to 
be applied in a country as it was not feasible to imple-
ment. Moreover, the WHO guidelines could be improved 
by not only describing the what, but the how of system-
atic screening including ACF, many interviewees said. 
One interviewee from an NGO in a low- income country 
suggested:
You can come up with different scenarios: ‘If the con-
text is this, then…’, ‘If the context is that, then…’. 
(…) Unless guidelines presents [the] ‘how’ better, 
(…) it’s meaningless. (I-7)
theme 5: sustainability of ACF
The sustainability of ACF was a cross- cutting theme in 
this analysis. Interviewees elaborated on opportunities 
and challenges related to sustainability. ‘TB is not a like 
smallpox or polio. It’s a long- term sustainable (…) matter,’ 
an independent consultant in a lower middle- income 
country described. (I-27)
That is, even more perseverance and long- term thinking 
may be required to end TB. Interviewees expressed 
similar views and concerns regarding this theme. Inter-
viewees highlighted that the interest in and leadership 
for ACF through the government and the National TB 
Programme are important for the sustainability of ACF. 
Additionally, the sustainability of ACF requires its integra-
tion in and funding through the given health system. An 
interviewee from an international organisation in a low- 
income country described:
If this [ACF] were to be sustainable, it should start with 
the initiation of the NTP [National TB Programme]. 
(…) It has to be supported, facilitated, monitored. 
Because it is actually the NTP which later needs to 
uptake that. (I-2)
Many interviewees highlighted the important role of 
National TB Programmes. The sustainability of ACF may 
be restricted in places with frequent government and 
staff turnover, which makes it difficult to get long- term 
commitment for ACF from decision- makers, interviewees 
stressed. Of course, such turnover will affect areas beyond 
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ACF. Also, ACF cannot be sustainable, if it depends on 
donor funding. One interviewee from an international 
organisation in a high- income country summarised the 
situation as follows:
It [ACF] is difficult to sustain. Most of the activities 
that have been done for ACF have been project- based. 
(…) So, the Global Fund comes and says: ‘Here is a pot 
of money for ACF for the next three years.’ (…) And 
then USAID [United States Agency for International 
Development] comes (…). Or TB REACH (…). And 
people do it. But that’s not a sustainable way of doing 
this and this should be part and parcel of routine pro-
gramming. (I-35)
DisCussiOn
In summary, this study highlighted experts’ perceived 
need for different types of evidence for ACF policy devel-
opment and implementation, and for stakeholder engage-
ment to foster evidence use. Interviewees stressed the 
influence of government, donor and NGO stakeholders 
as influential players in ACF policy development. Such 
key stakeholders also influence ACF policy implementa-
tion, in addition to available systems and processes in a 
given health system and implementers’ motivation and 
incentives. The WHO guidelines for systematic screening 
were said to face the innate challenge of covering the 
broad area of ACF in terms of target groups, settings and 
screening algorithms. Interviewees suggested that the 
guidelines could be improved by incorporating new and 
different types of evidence, by focusing on what should 
be done rather than what can be done and by providing 
examples of the how of ACF. Finally, for ACF to be sustain-
able, interviewees stressed the need for leadership for 
ACF, its integration into health systems and the transition 
from donor to government funding.
building on a broad evidence base
Interviewees emphasised the need for a variety of 
evidence, such as impact and economic evaluations, oper-
ational and qualitative research. Qualitative evidence has 
proven essential in developing and implementing health 
policies including in low- and middle- income countries, 
for example, to prevent and treat malaria during preg-
nancy.25 In the case of ACF, decision- makers may need 
qualitative evidence on, for instance, factors influencing 
participation in ACF or the retention of health workers. 
Likewise, qualitative evidence syntheses have emerged 
as an important approach to inform national and global 
health policy development and implementation26 and 
could also be useful for improving future ACF policies.
Making and implementing better ACF policies through 
stakeholder engagement
Successful ACF policy development and implementation 
necessitate stakeholder engagement, interviewees high-
lighted. Stakeholder engagement is an inclusive process 
essential for achieving legitimate decisions, which are 
accepted by the population and conducive to effective 
implementation.27 Specifically, interviewees stressed the 
importance of community engagement to enhance the 
implementation of ACF. Available evidence also shows 
the importance of community engagement and support 
for ACF implementation, for example, through collabo-
ration with respected community leaders (ie, chiefs, civic 
leaders, village elders and counsellors).28 29 In addition, 
familiarity with the community30 and community buy- in31 
as well as community appreciation and respect through 
the engagement of community health workers was said 
to be important.32 33 Stakeholder engagement is also rele-
vant for the development of WHO guidelines at the global 
level, and their adaptation to the national or subnational 
levels, where a wide array of stakeholders with diverse sets 
of values should be involved.34 35
Moving from ‘paralyzing’ to ‘empowering’ WhO guidance
The interviewees had many suggestions for improving 
the WHO guidelines on systematic screening,9 ques-
tioning the appropriateness of only using the GRADE 
approach in the context of ACF. The WHO guidelines 
make graded recommendations about screening specific 
risk groups for TB, including three strong recommenda-
tions (screening in household contacts and other close 
contacts, people living with HIV and current and former 
workers in workplaces with silica exposure) and four 
conditional recommendations (screening among pris-
oners, in people with an untreated fibrotic lesion seen 
on chest X- ray, in settings where the TB prevalence in the 
general population is 100/100 000 population or higher, 
in geographically defined subpopulations with extremely 
high levels of undetected TB and other subpopulations 
that have very poor access to healthcare).9 The condition-
ality makes decision- making in ACF complex by leaving 
recommendations open to interpretation. For instance, 
the conditionality may ‘paralyze’ decision- makers to 
move screening outside of health facilities, as ACF in 
many vulnerable groups is only conditionally recom-
mended. However, despite conditional recommendations 
and ‘low- quality’ or ‘very low- quality evidence’ that all of 
the WHO’s recommendations on systematic screening 
are based on,9 decision- makers must still act, either in 
deciding to implement or taking the decision not to. The 
Global Fund and TB REACH can provide guidance in 
interpreting the guidelines. Yet, countries should guar-
antee that these interpretations and adaptations are 
based on the local epidemiology, health system capacity, 
resources, feasibility, effects and economic impact, and so 
on. This would be paramount in order not to move away 
from the guidelines’ original intention. Ensuring contin-
uous monitoring and evaluation is therefore important.36 
GRADE- Confidence in the Evidence from Reviews of 
Qualitative Research37 38 may be a useful resource for 
future global systematic TB screening guideline develop-
ment. It has been developed to assess confidence in find-
ings from qualitative evidence syntheses. Additionally, 
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the GRADE Evidence to Decision Framework for Health 
System and Public Health Decisions36 or the WHO- 
INTEGRATE Evidence to Decision Framework39 could 
be valuable to assess evidence for a complex intervention 
such as ACF.
integrating ACF into health systems for sustainability
Interviewees underlined the need to integrate ACF into a 
given health system for it to be sustainable. Such integra-
tion may start with an assessment of the given health system 
context to understand available structures (eg, infrastruc-
ture, budget structure and trained human resources) and 
processes (eg, supportive supervision and monitoring). 
Interviewees described these resources as being para-
mount to link to and build on. The fact that participants 
highlighted the need for health system integration, which 
seems to be relevant for any health intervention, may indi-
cate that such integration cannot be taken for granted 
and/or might not always occur in ACF. It is important to 
acknowledge that ‘integration’ may describe a variety of 
organisational arrangements across different settings.40 
Additionally, in many low- income countries, interven-
tions generally operate through a complex patchwork of 
arrangements, rather than through totally stand- alone or 
totally integrated approaches.41
To embed ACF into health systems, available systems for 
outreach and health promotion,4 laboratory networks42 
and free services43 have been highlighted. Moreover, 
given the importance of community health workers for 
implementing ACF, their integration into the health 
system has been emphasised.44 45 Importantly, the collab-
oration between various actors has been described as key 
for sustainable ACF implementation. The latter includes 
collaboration between public health practitioners and clini-
cians,46 district TB teams and government health staff,47 
healthcare staff and community health workers.30 44 More-
over, collaboration between HIV and TB sectors,48 with 
laboratory staff44 and with community organisations48 49 
has been described as important. Government, National 
TB Programmes, WHO and donors, whose key roles in 
ACF policy development and implementation have been 
described by the interviewees, should contribute to the 
long- term thinking and long- term action related to ACF 
and towards ending TB. Murphy and Fafard50 emphasise 
that only a mix of appropriate evidence, key stakeholders, 
processes and structures would be a solution for evidence- 
informed policy development and implementation.
Future research
Implementation research that sheds light on what works 
for whom and under which conditions may be particularly 
helpful to answer some of the how questions which our 
study exposed. Moreover, operational research that uses 
available local data, for example, on TB notifications, may 
help inform local decision- making around ACF. Finally, 
mixed methods studies can help explore the complexity 
of ACF policy development and implementation in the 
future, as they have the potential to both increase contex-
tual understanding and reduce biases.
strengths and limitations
While the available evidence in this area often focuses on 
ACF policy implementation,51 this study fills important 
knowledge gaps by identifying factors influencing ACF 
policy development and characterising evidence use in 
ACF policy development and implementation, from the 
perspective of experts in the field. Moreover, this study 
offers an increased understanding of donor organisa-
tions’ influence on ACF policy processes. The number 
and diverse range of experts involved in this study, as 
well as the member checking carried out, increase the 
study’s trustworthiness, including its confirmability and 
transferability.20 The transferability of this study’s results 
may be limited given that only a minority of the experts 
were from low- and middle- income countries (38%; 15 
out of 39 experts). Nevertheless, all had working expe-
rience from low- and middle- income countries. Seven 
of the interviews with experts from low- and middle- 
income countries were conducted with experts from 
Nepal. Though all of them have different affiliations, 
their perspectives may be over- represented. The results 
may furthermore be limited as an even smaller minority 
were women (18%; 7 out of 39 experts). The gender bias 
reflects the lack of gender parity in leadership positions 
in the field of global health.52 We did not systematically 
conduct analyses by stakeholder group but described the 
patterns we observed and highlighted the affiliations of 
interviewees quoted.
COnClusiOn
Based on a variety of experts’ perspectives, we gener-
ated new insights on ACF policy processes, in particular 
regarding facilitators for and barriers to ACF policy devel-
opment, evidence need and use, and donor organisations’ 
influence. Still, we know little about how to strengthen 
those facilitators, how to overcome those barriers and 
how to strengthen research use. Bringing together these 
different views creates a more comprehensive picture of 
ACF policy development and implementation today and 
indicates ways to strengthen such processes in the future: 
national and global ACF policy development and imple-
mentation can be improved by broadening stakeholder 
engagement and ownership; from decision- makers at the 
Ministry of Health to community leaders and members. 
Meanwhile, using diverse evidence to inform ACF policy 
development and implementation could mitigate the 
‘power plays plus push’ that might otherwise disrupt and 
mislead these policy processes. Our findings complement 
the existing evidence base and can inform future national 
and global ACF policy processes.
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